文献速递心外重症与机械循环支持

MOMENTUM 3 试验 6 个月时生活质量与功能容量结局:呼吁为左心室辅助装置患者制定新指标

Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients.
PubMed 文献 · J Heart Lung Transplant · 2017-10-24

MOMENTUM 3 临床试验在 HeartMate 3(HM3,n=151)与 HeartMate II(HMII,n=138)植入后基线与 6 个月评估功能容量(NYHA、6 分钟步行试验)与健康相关生活质量(EQ-5D-5L、KCCQ)。两装置 6 个月 KCCQ 与 EQ-5D-5L 均较基线改善但组间无差异;发生严重不良事件(SAE,n=188)者 6 分钟步行试验增益低于无 SAE 者,但 SAE 未影响 6 个月生活质量评分。「良好生活」终点 HM3 145 例(63%)vs HMII 120 例(68%)(p=0.44)。作者认为需要开发左心室辅助装置专用生活质量工具。

要点

  • HM3 与 HMII 植入后 6 个月 KCCQ 与 EQ-5D-5L 均较基线改善,但两装置间无差异(p>0.05)。
  • 发生 SAE 者 6 分钟步行试验增益低于无 SAE 者(HM3:+74 米 vs +140 米;HMII:+177 米 vs +192 米,均 p<0.003)。
  • SAE 未影响 6 个月健康相关生活质量评分;作者呼吁开发左心室辅助装置专用生活质量工具。

核心结论

  • HM3 与 HMII 植入后早期健康相关生活质量与功能容量增益相似。
  • 发生 SAE 的患者 6 分钟步行试验改善减弱,但健康相关生活质量指标未变化。
  • 作者认为需要开发左心室辅助装置专用健康相关生活质量工具,以更好地描述 SAE 对患者福祉的影响。

研究设计与样本

  • MOMENTUM 3 临床试验的一部分,在基线与 6 个月评估功能容量(NYHA、6 分钟步行试验)与健康相关生活质量(EQ-5D-5L、KCCQ)。
  • HM3 组 n=151,HMII 组 n=138,均为 Abbott 装置。
  • 比较两装置间以及有无事件患者的指标,并评估 6 个月「良好生活于 LVAS」的比例。

主要发现

  • KCCQ 变化中位数(25-75 百分位):HM3 +28(10-46),HMII +29(9-48),较基线改善(p<0.05),组间无差异(p>0.05)。
  • EQ-5D-5L 变化中位数(25-75 百分位):HM3 -1(-5 至 0),HMII -2(-6 至 0),较基线改善(p<0.05),组间无差异(p>0.05)。
  • 6 分钟步行试验距离 6 个月较基线改善:HM3 +94(1-274)米,HMII +188(43-340)米。
  • SAE 患者(n=188)6 分钟步行试验较基线增加(p<0.001),但增益低于无 SAE 者:HM3 +74(-9 至 183)米 vs +140(35-329)米;HMII +177(47-356)米 vs +192(23-337)米,均 p<0.003。
  • 「良好生活」终点达成:HM3 145 例(63%)vs HMII 120 例(68%)(p=0.44)。

关键数值与推荐

  • 「良好生活于 LVAS」定义为存活且功能容量满意(NYHA I/II 或 6 分钟步行试验 >300 米)且健康相关生活质量满意(KCCQ 总分 >50)。

临床怎么用

  • 作者认为需要开发左心室辅助装置专用健康相关生活质量工具,以更好地描述 SAE 对患者福祉的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Multicenter Study of MAGLEV Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial demonstrated improved 6-month event-free survival, but a detailed analysis of health-related quality of life (HR-QOL) and functional capacity (FC) was not presented. Further, the effect of early serious adverse events (SAEs) on these metrics and on the general ability to live well while supported with a left ventricular assist system (LVAS) warrants evaluation. METHODS: FC (New York Heart Association [NYHA] and 6-minute walk test [6MWT]) and HR-QOL (European Quality of Life [EQ-5D-5L] and the Kansas City Cardiomyopathy [KCCQ]) assessments were obtained at baseline and 6 months after HeartMate 3 (HM3, n = 151; Abbott, Abbott Park, IL) or HeartMate II (HMII, n = 138; Abbott) implant as part of the MOMENTUM 3 clinical trial. Metrics were compared between devices and in those with and without events. The proportion of patients "living well on an LVAS" at 6 months, defined as alive with satisfactory FC (NYHA I/II or 6MWT > 300 meters) and HR-QOL (overall KCCQ > 50), was evaluated. RESULTS: Although the median (25th-75th percentile) patient KCCQ (change for HM3: +28 [10-46]; HMII: +29 [9-48]) and EQ-5D-5L (change for HM3: -1 [-5 to 0]; HMII: -2 [-6 to 0]) scores improved from baseline to 6 months (p < 0.05), there were no differences between devices (p > 0.05). Likewise, there was an equivalent improvement in 6MWT distance at 6 months in HM3 (+94 [1-274] meters] and HMII (+188[43-340 meters]) from baseline. In patients with SAEs (n = 188), 6MWTs increased from baseline (p < 0.001), but gains for both devices were less than those without SAE (HM3: +74 [-9 to 183] meters with SAE vs +140 [35-329] meters without SAE; HMII: +177 [47-356] meters with SAE vs +192 [23-337] meters without SAE, both p < 0.003). SAEs did not affect the 6-month HR-QOL scores. The "living well" end point was achieved in 145 HM3 (63%) and 120 HMII (68%) patients (p = 0.44). CONCLUSIONS: Gains in HR-QOL and FC were similar early after HM3 and HMII implant. 6MWT improvements were attenuated in patients experiencing SAEs, but HR-QOL metrics did not change. The development of left ventricular assist device-specific HR-QOL tools is needed to better characterize the effect of SAEs on a patient's well-being. CLINICAL TRIAL NO: MOMENTUM 3 clinical trial #NCT02224755.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Cowger JA, Naka Y, Aaronson KD, et al. Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients. J Heart Lung Transplant. 2017. PMID: 29153637. doi:10.1016/j.healun.2017.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。